• AstraZeneca average debt/equity ratio for 2024 was 0.7, a 9.38% decline from 2023.
• AstraZeneca average debt/equity ratio for 2023 was 0.64, a 8.57% increase from 2022.
• AstraZeneca average debt/equity ratio for 2022 was 0.7, a 33.33% decline from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.